FLGR242: Albumin-Bound Follistatin Variant
A vendor-marketed modified Follistatin construct with a serum-albumin-binding domain claimed to extend half-life to ~19 days. Critically: no peer-reviewed publications on FLGR242 itself exist.
How It Works
Follistatin (FST) is a naturally occurring TGF-β superfamily inhibitor that binds and neutralizes myostatin (GDF-8) and activin. Inhibition of myostatin lifts a brake on skeletal muscle growth — the basis for every follistatin-based muscle research program. (PMID 19208403)
Vendors describe FLGR242 as a Follistatin variant fused to an albumin-binding domain via a glycine-serine linker. Vendor materials claim the modification produces selective myostatin binding without activin binding, which would in principle reduce off-target endocrine effects of natural FST. This claim has not been independently verified in peer review.
Albumin-binding domains extend peptide half-life by piggy-backing on the long circulation time of human serum albumin (~19 days). This is a validated half-life-extension strategy used in approved drugs (e.g., GLP-1 analogs). (PMID 33049303, 33386550)
Myostatin loss-of-function produces gross muscle hypertrophy in humans (Schuelke 2004 NEJM, PMID 15215484). Transgenic FS288 (a follistatin isoform) reverses dystrophic pathology in mdx mice (PMID 17893249). AAV-Follistatin gene therapy improved walking in Becker MD and inclusion-body myositis (PMID 25322757, 27858738, 28279643). The pathway is real; FLGR242's claim to engage it is the unverified part.
What the Data Shows
Key Takeaways
- Myostatin is a real, well-characterized negative regulator of skeletal muscle mass — its loss produces gross hypertrophy in humans (PMID 15215484).
- Natural Follistatin and its FS288 isoform inhibit myostatin and rescue dystrophic muscle in mice (PMID 17893249, 19208403).
- AAV-delivered Follistatin gene therapy improved 6-minute walk and functional measures in Becker MD and sporadic IBM phase 1/2a trials (PMID 25322757, 27858738, 28279643).
- Albumin-binding-domain peptide engineering is a validated half-life extension strategy with FDA-approved precedent (PMID 33049303, 33386550).
- FLGR242 is sold as a research-grade peptide by multiple vendors (BioLongevity Labs, Paramount Peptides, Peptide Labs, Alpha BioMed).
- There are ZERO PubMed-indexed studies on FLGR242 specifically. The compound has not been characterized in peer-reviewed literature.
- The vendor claim of "no activin binding" has not been independently verified — natural Follistatin binds both myostatin AND activin, and selectivity engineering is non-trivial.
- The 19-day half-life is a vendor figure with no published pharmacokinetic data.
- No human or peer-reviewed animal efficacy data exists for FLGR242 — claims of muscle growth in humans are speculative.
- Long-acting follistatin biology is double-edged: chronic myostatin inhibition raises theoretical concerns about cardiac muscle, tendon strength, and ovarian/HPG axis effects (since activin signaling controls FSH).
- FLGR242 is NOT FDA-approved, NOT a drug, and any human use is unregulated research.
Frequently Asked Questions
What is FLGR242?
FLGR242 is the vendor name for a synthetic modified Follistatin construct sold by several research-peptide suppliers. Vendor materials describe it as Follistatin fused with an albumin-binding domain via a glycine-serine linker, with the goal of extending circulating half-life (claimed ~19 days). No peer-reviewed publication uses the "FLGR242" designation as of this writing.
Is there any peer-reviewed research on FLGR242?
No. A PubMed search for "FLGR242" returns zero results. The compound's claimed mechanism (albumin-binding-extended myostatin-selective Follistatin variant) is plausible — both the half-life extension strategy (PMID 33049303, 33386550) and the underlying Follistatin/myostatin biology (PMID 15215484, 19208403, 17893249, 25322757, 27858738, 28279643) are well-supported. But the specific FLGR242 construct has not been characterized in peer review.
How is FLGR242 different from Follistatin-344 (FST-344)?
Natural Follistatin exists in multiple isoforms (FS288, FS300, FS315 / FST-344) that differ in heparin-binding and cell-surface affinity. Vendor materials position FLGR242 as a fragmented/modified FST-344 derivative engineered for two changes: (1) addition of an albumin-binding domain for long half-life, (2) selective binding to myostatin but NOT activin. The activin-selectivity claim is the more aggressive of the two — natural FST binds both — and independent biochemical verification has not been published.
Could FLGR242 actually grow muscle in humans?
The biology supports a positive answer in principle: myostatin loss produces dramatic muscle hypertrophy in humans (Schuelke NEJM 2004, PMID 15215484), and AAV-Follistatin gene therapy has improved measurable function in Becker MD and IBM trials (PMID 25322757, 27858738, 28279643). Whether the FLGR242 construct specifically delivers myostatin inhibition in vivo at safe doses has not been published. Treat strong-claim marketing skeptically until peer-reviewed pharmacokinetic and efficacy data exist.
Is FLGR242 FDA-approved or safe?
No. FLGR242 is not FDA-approved and is sold for laboratory research use only. Even setting the FLGR242 construct aside, chronic systemic myostatin inhibition raises real safety questions — cardiac muscle effects, tendon-to-muscle strength mismatch with hypertrophy, and downstream FSH / HPG-axis effects if activin signaling is partially blocked. No human safety database for FLGR242 exists.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
📚 Related HighPeptides Research
Educational purposes only. Not medical advice.
FLGR242 has ZERO peer-reviewed publications. Vendor claims about mechanism, half-life, and selectivity are unverified.
FLGR242 is NOT FDA-approved. Not a drug. No claims about treating, diagnosing, or preventing any disease.
Chronic myostatin inhibition has unresolved safety concerns regarding cardiac muscle, tendon strength, and HPG-axis effects.